• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Feb 15, 1991; 88(4): 1494–1498.
PMCID: PMC51045

Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?

Abstract

The neurohypophyseal neuropeptides (Arg8)-vasopressin (AVP) and [pGlu4,Cyt6]AVP-(4-8) (where pGlu is pyroglutamic acid and Cyt is cystine) facilitate the retention of one-trial-learning passive avoidance behavior in rats when administered into the cerebral ventricle immediately after the learning trial. The fragment [pGlu4,Cyt6]AVP-(4-8) was considerably more effective than AVP. Oxytocin (OXT) and [pGlu4,Cyt6]OXT-(4-8) have the opposite effect and attenuate passive avoidance behavior also when administered into the cerebral ventricle after the learning trial. Again the fragment was more active than the parent molecule. The ancient arginine-containing neurohypophyseal hormone vasotocin in "high" doses (10ng) had a vasopressin-like effect and in "low" doses (0.1 ng) had an OXT-like effect on passive avoidance behavior. Because both vasopressinergic (V1) and oxytocinergic receptors have been demonstrated in the central nervous system, we asked whether specific antagonists of the V1, V2, and OXT receptor could antagonize the effects of these neuropeptides on passive avoidance behavior. The three antagonists were approximately equally active in blocking the effect of vasopressin, whereas the fragment [pGlu4]AVP-(4-8) and the high dose of vasotocin were more readily blocked by the OXT antagonist. The attenuating effect of OXT, the fragment [pGlu4,Cyt6]OXT-(4-8), and the low dose of vasotocin was markedly reduced by the OXT antagonist. This effect could also be reduced by pretreatment with the V1 antagonist but not with the V2 antagonist. These results suggest the existence of a separate neurohypophyseal hormone receptor complex in the brain affecting memory processes that differs from the peripheral V1, V2, and OXT receptor.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • de Wied D. Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments. Life Sci. 1976 Sep 1;19(5):685–690. [PubMed]
  • van Wimersma Greidanus TB, van Ree JM, de Wied D. Vasopressin and memory. Pharmacol Ther. 1983;20(3):437–458. [PubMed]
  • Kovács GL, Szabó G, Sarnyai Z, Telegdy G. Neurohypophyseal hormones and behavior. Prog Brain Res. 1987;72:109–118. [PubMed]
  • Barberis C. [3H]vasopressin binding to rat hippocampal synaptic plasma membrane. Kinetic and pharmacological characterization. FEBS Lett. 1983 Oct 17;162(2):400–405. [PubMed]
  • Dorsa DM, Petracca FM, Baskin DG, Cornett LE. Localization and characterization of vasopressin-binding sites in the amygdala of the rat brain. J Neurosci. 1984 Jul;4(7):1764–1770. [PubMed]
  • Audigier S, Barberis C. Pharmacological characterization of two specific binding sites for neurohypophyseal hormones in hippocampal synaptic plasma membranes of the rat. EMBO J. 1985 Jun;4(6):1407–1412. [PMC free article] [PubMed]
  • De Kloet ER, Rotteveel F, Voorhuis TA, Terlou M. Topography of binding sites for neurohypophyseal hormones in rat brain. Eur J Pharmacol. 1985 Mar 26;110(1):113–119. [PubMed]
  • Koob GF, Le Moal M, Gaffori O, Manning M, Sawyer WH, Rivier J, Bloom FE. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats. Regul Pept. 1981 Jun;2(3):153–163. [PubMed]
  • Le Moal M, Koob GF, Koda LY, Bloom FE, Manning M, Sawyer WH, Rivier J. Vasopressor receptor antagonist prevents behavioural effects of vasopressin. Nature. 1981 Jun 11;291(5815):491–493. [PubMed]
  • de Wied D, Gaffori O, van Ree JM, de Jong W. Central target for the behavioural effects of vasopressin neuropeptides. Nature. 1984 Mar 15;308(5956):276–278. [PubMed]
  • Burbach JP, Kovács GL, de Wied D, van Nispen JW, Greven HM. A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. Science. 1983 Sep 23;221(4617):1310–1312. [PubMed]
  • Kovács GL, De Wied D. Hormonally active arginine-vasopressin suppresses endotoxin-induced fever in rats: lack of effect of oxytocin and a behaviorally active vasopressin fragment. Neuroendocrinology. 1983 Oct;37(4):258–261. [PubMed]
  • Cheng SW, North WG. Vasopressin reduces release from vasopressin-neurons and oxytocin-neurons by acting on V2-like receptors. Brain Res. 1989 Feb 6;479(1):35–39. [PubMed]
  • Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J Med Chem. 1980 Apr;23(4):364–368. [PubMed]
  • Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng LL, Klis WA, Seto J, Haldar J, Sawyer WH. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J Med Chem. 1989 Feb;32(2):382–391. [PubMed]
  • Manning M, Nawrocka E, Misicka A, Olma A, Klis WA, Seto J, Sawyer WH. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4. J Med Chem. 1984 Apr;27(4):423–429. [PubMed]
  • Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol. 1986 Aug;30(2):171–177. [PubMed]
  • Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. [PubMed]
  • Kovács GL, Veldhuis HD, Versteeg DH, De Wied D. Facilitation of avoidance behavior by vasopressin fragments microinjected into limbic-midbrain structures. Brain Res. 1986 Apr 16;371(1):17–24. [PubMed]
  • Bohus B, Urban I, van Wimersma Greidanus TB, de Wied D. Opposite effects of oxytocin and vasopressin on avoidance behaviour and hippocampal theta rhythm in the rat. Neuropharmacology. 1978 Apr-May;17(4-5):239–247. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...